CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 176,954	$ 131,329
Marketable securities	246,459	510,094
Interest receivable	620	1,035
Accounts receivable	7,967	5,224
Prepaid expenses and other current assets	15,396	11,986
Total current assets	447,396	659,668
Marketable securities, non-current	95,631	50,530
Property and equipment, net	50,816	41,324
Intangible assets	54,928	58,128
Goodwill	40,530	42,798
Operating lease right-of-use assets	66,227	71,045
Other non-current assets	15,370	13,557
Restricted cash	1,500	1,500
Total assets	772,398	938,550
Current liabilities:
Accounts payable	7,982	12,553
Accrued compensation and employee benefits	18,646	20,738
Other accrued liabilities	14,816	18,612
Deferred revenues	90,454	91,644
Total current liabilities	131,898	143,547
Deferred revenues, non-current	183,943	245,045
Long-term portion of lease liabilities	36,121	38,396
Deferred income tax	6,789	7,185
Other non-current liabilities	7,631	7,011
Total liabilities	366,382	441,184
Commitments
Stockholders’ equity:
Preferred stock	0	0
Common stock	1,455	1,421
Additional paid-in capital	1,323,955	1,269,375
Accumulated deficit	(918,771)	(777,981)
Accumulated other comprehensive (loss) income	(623)	5,419
Total Sangamo Therapeutics, Inc. stockholders’ equity	406,016	498,234
Non-controlling interest	0	(868)
Total stockholders’ equity	406,016	497,366
Total liabilities and stockholders’ equity	$ 772,398	$ 938,550